# Final Report: Idea 92

## Final ELO Score: 1210.4

## Final Hypothesis

**Title**: Tunicamycin-Loaded PLGA Nanoparticles plus CRISPRi-tarF for Systemic-Safe Synthetic Lethality

**Key Idea**: PLGA nanoparticles shield ultra-low tunicamycin doses from renal tissue, while CRISPRi-tarF plasmids delivered by phagemids create synthetic lethality in S. aureus.

**Paragraph**: Nanoparticle encapsulation halves tunicamycin Cmax below nephrotoxic levels; phagemid CRISPRi achieves transient tarF knockdown.

**Approach**: Renal cytotoxicity assays; biofilm-coated implant model; rat PK; efficacy.

**Key References**: Campbell 2011; SantaMaria 2014; Tong 2015; NEW—Feng et al., Biomaterials, 2021 (PLGA renal safety) [Feng 2021].  
Modifications: Added PLGA shielding for systemic safety and phage-mediated CRISPRi delivery.

────────────────────────────────────────────────────────
IDEA 57  
────────────────────────────────────────────────────────

## Comprehensive Analysis

This document provides a full analysis of the idea, including its evolution, strengths, weaknesses, and potential applications. Below we trace the development of this idea through each phase of the research process.

## Evolution History

The idea underwent several iterations during the research process:

## Detailed Breakdown

### Title

Tunicamycin-Loaded PLGA Nanoparticles plus CRISPRi-tarF for Systemic-Safe Synthetic Lethality

### Key Idea

PLGA nanoparticles shield ultra-low tunicamycin doses from renal tissue, while CRISPRi-tarF plasmids delivered by phagemids create synthetic lethality in S. aureus.

### Detailed Explanation

Nanoparticle encapsulation halves tunicamycin Cmax below nephrotoxic levels; phagemid CRISPRi achieves transient tarF knockdown.

### Implementation Approach

Renal cytotoxicity assays; biofilm-coated implant model; rat PK; efficacy.

### Key References

Campbell 2011; SantaMaria 2014; Tong 2015; NEW—Feng et al., Biomaterials, 2021 (PLGA renal safety) [Feng 2021].  
Modifications: Added PLGA shielding for systemic safety and phage-mediated CRISPRi delivery.

────────────────────────────────────────────────────────
IDEA 57  
────────────────────────────────────────────────────────

## Complete Evolution History

This section documents the complete evolution of the idea through each phase of the research process.

### 1. Evolution (Round 4)
**Timestamp:** 2025-05-07 10:43:26



### 2. Reflection (Round 4)
**Timestamp:** 2025-05-07 10:44:53



### 3. Proximity Check (Round 4)
**Timestamp:** 2025-05-07 10:45:31



### 4. Ranking (Round 4)
**Timestamp:** 2025-05-07 10:45:39



### 5. Round Summary (Round 4)
**Timestamp:** 2025-05-07 10:46:18



### 6. Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1210.4



### 7. Final Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1210.4



## Citations

- Feng 2021
